An experimental weight loss drug, retatrutide, has demonstrated encouraging results in helping obese adults lose weight. Randomized controlled trials (RCTs) assessed the efficacy and safety of ...

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...

Retatrutide is a synthetic peptide, which research indicates functions as a triple agonist for type 2 diabetes and weight loss. Peptides, small chains of amino acids, have been hypothesized to ...

placebo across 26 randomized studies. Retatrutide conferred the greatest weight reduction among all GLP-1s. A dozen GLP-1 receptor agonists and coagonists demonstrated effectiveness for weight ...